E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1436-3305
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function ; day:31 ; month:7 ; year:2018 ; pages:1-14
Gastric cancer ; (31.7.2018), 1-14
- Urheber
-
Godwin, Tanis D.
- Beteiligte Personen und Organisationen
-
Kelly, S. Thomas
Brew, Tom P.
Bougen-Zhukov, Nicola M.
Single, Andrew B.
Chen, Augustine
Stylianou, Cassie E.
Harris, Lawrence D.
Currie, Sophie K.
Telford, Bryony J.
Beetham, Henry G.
Evans, Gary B.
Black, Michael A.
Guilford, Parry J.
SpringerLink (Online service)
- DOI
-
10.1007/s10120-018-0859-1
- URN
-
urn:nbn:de:101:1-2018100220455719197106
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Godwin, Tanis D.
- Kelly, S. Thomas
- Brew, Tom P.
- Bougen-Zhukov, Nicola M.
- Single, Andrew B.
- Chen, Augustine
- Stylianou, Cassie E.
- Harris, Lawrence D.
- Currie, Sophie K.
- Telford, Bryony J.
- Beetham, Henry G.
- Evans, Gary B.
- Black, Michael A.
- Guilford, Parry J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Identifying collateral and synthetic lethal vulnerabilities within the DNA-damage response
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers
The biology and molecular vulnerabilities of ATM-deficient cancers
Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer
Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells
Synthetic lethal treatment strategies for tumor cell senescence
Epigenetic based synthetic lethal strategies in human cancers
Exploiting genetic vulnerabilities for BAP1 loss by synthetic lethality
Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality
Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal
Identifying collateral and synthetic lethal vulnerabilities within the DNA-damage response
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers
The biology and molecular vulnerabilities of ATM-deficient cancers
Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer
Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells
Synthetic lethal treatment strategies for tumor cell senescence
Epigenetic based synthetic lethal strategies in human cancers
Exploiting genetic vulnerabilities for BAP1 loss by synthetic lethality
Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality
Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal
Identifying collateral and synthetic lethal vulnerabilities within the DNA-damage response
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers
The biology and molecular vulnerabilities of ATM-deficient cancers
Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer
Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells
Synthetic lethal treatment strategies for tumor cell senescence
Epigenetic based synthetic lethal strategies in human cancers
Exploiting genetic vulnerabilities for BAP1 loss by synthetic lethality
Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality